WASHINGTON, D.C. – June 15, 2015 – Today Comprehend Systems, Inc., the leader in clinical software solutions, announced the launch ofContinuous Quality for ClinOps, a solution that enables clinical operations (ClinOps) to deliver high quality clinical trial submissions at a new speed. This cloud-based solution unifies and analyzes ClinOps data and automates alerts and collaboration across executives, teams and contract research organizations (CROs). Clinical trial leaders can now focus on what matters and act faster while improving quality, hitting milestones and speeding the delivery of a portfolio of clinical trials.With this additional visibility into trials, life sciences companies can improve trial quality and speed to deliver trial results and get life-saving drugs and devices to market even faster. The solution is being unveiled at the DIA 51st Annual Meeting in Washington, D.C. in booth 2511.
Clinical trial leaders at pharmaceutical, medical device and diagnostics companies operate with chronic uncertainty about the quality of their trial data due to the inconsistency of current manual processes and data. This poor data quality slows down results, which is why a mere 10 percent of clinical trials finish on time and 80 percent of trials regularly miss milestones.
Today, outdated processes are used to collect, analyze and understand patient outcomes and produce three main challenges:
· Lack of real-time access to operational and clinical data
· Difficult and slow to investigating risks and outliers
· Complexity of cross-functional collaboration
Overall, ClinOps teams lack the transparency and processes needed to make critical decisions that deliver quality submissions while adhering to regulatory standards within the scheduled timeframe.
“Today’s method of bringing new drugs and devices to market is broken. Many organizations, big and small, are still using Excel spreadsheets and other manual methods to manage clinical trials, often leading to missed milestones and poor data quality,” said Rick Morrison, CEO and co-founder of Comprehend. “Fortunately, technology is completely transforming this antiquated approach, and Comprehend is at the forefront of this transition.
"As we push to modernize clinical trials, we bring new speed to quality results.”
Comprehend’s Continuous Quality Solution for ClinOps’ gives life sciences companies a new source of competitiveness and the confidence to deliver high quality clinical trial submissions at a new speed. With a user-centric and purpose-built design, the solution is accessible on any device and is fully compliant and validated (21 CFR Part 11). The solution automates the continuous quality lifecycle, features include:
SeeEverything
· Analytics and Visualizations inform your decision-making and collaboration processes on site and operational performance, safety, efficacy and compliance
Focus on What Matters
· Filtering enables end users to remove redundant or unwanted data from the info stream to facilitate exploration and cohort analysis
Actively Investigate
· Click-through enables the user to broaden or narrow their exploration from portfolio views down to granular study data even with unique data models across studies
Make Smarter Decisions
· Forecasts for key indicators that predict future outcomes based on historic facts
· Cross Study Benchmarking uses current similar and past trials to inform decisions on current trials
ActFaster
· Monitoring system tracks trends and allows user-driven thresholds to raise events in the system. Early warnings enable ClinOps leaders to take preventative action
· Collaboration provides decentralized users with simultaneous views of analytics and ability to create data-driven tasks and workflows
· Alerts and Notifications of events can be in app or email or both
Fully Defend
· Audit trails allows full auditability of system state from any point in time, including user activity for compliance and report configuration for decision history
Visit Comprehend’s DIA booth 2511 for a product demo or contact us at info@comprehend.com for a virtual demo.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.